Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma
CD320, SLC44A1, and TNFRSF13B are promising, clinically relevant targets for CAR T-cell therapy in MM. Their stage-specific expression and prognostic significance support their potential to enhance existing immunotherapeutic strategies.
Authors
- Francesca Garofano (ORCID: https://orcid.org/0009-0005-4698-0264)
- Anna Maria Corsale (ORCID: https://orcid.org/0000-0002-2541-4619)
- S. Siragusa
- Marta Biondo
- Cirino Botta
- Anna Maria Gullà
- Andrea Romano
- Ingo Schmidt-Wolf
Institutions
- University Hospital Bonn (DE)
- University of Catania (IT)
- Candiolo Cancer Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Palermo (IT)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-13
- DOI
- https://doi.org/10.3389/fmed.2025.1737919
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 35.41
Funders
- European Commission
- Associazione Italiana per la Ricerca sul Cancro